

Afshin Dowlati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9353017/publications.pdf>

Version: 2024-02-01

108
papers

14,232
citations

136885

32
h-index

33869

99
g-index

108
all docs

108
docs citations

108
times ranked

14609
citing authors

#	ARTICLE	IF	CITATIONS
1	Paclitaxel+Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 2542-2550.	13.9	5,525
2	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	13.9	2,036
3	Durvalumab plus platinum+etoposide versus platinum+etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	6.3	1,274
4	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019, 19, 289-297.	12.8	692
5	Larotrectinib in patients with <i>TRK</i> fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	5.1	608
6	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , 2017, 31, 286-299.	7.7	370
7	Durvalumab, with or without tremelimumab, plus platinum+etoposide versus platinum+etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	5.1	356
8	A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. <i>Cancer Research</i> , 2002, 62, 3408-16.	0.4	321
9	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2386-2394.	0.8	276
10	Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study. <i>Clinical Cancer Research</i> , 2008, 14, 1407-1412.	3.2	260
11	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966.	3.2	206
12	A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome. <i>Thyroid</i> , 2009, 19, 233-240.	2.4	174
13	Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501. <i>Journal of Clinical Oncology</i> , 2009, 27, 6006-6011.	0.8	148
14	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	3.4	127
15	Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 73745-73756.	0.8	114
16	A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers. <i>Clinical Cancer Research</i> , 2009, 15, 3583-3590.	3.2	92
17	Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance). <i>Journal of Thoracic Oncology</i> , 2017, 12, 704-713.	0.5	71
18	Clinical correlation of extensive-stage small-cell lung cancer genomics. <i>Annals of Oncology</i> , 2016, 27, 642-647.	0.6	69

#	ARTICLE	IF	CITATIONS
19	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2021, 124, 744-753.	2.9	65
20	Combined SCLC Clinical and Pathologic Characteristics. <i>Clinical Lung Cancer</i> , 2013, 14, 113-119.	1.1	64
21	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 87-97.	1.2	59
22	RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. <i>Oncotarget</i> , 2017, 8, 5992-6002.	0.8	55
23	Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2007, 55, 349-355.	0.9	50
24	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	3.2	48
25	Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3 line small cell lung cancer: Results from the phase 2 TRINITY study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8507-8507.	0.8	48
26	Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 459-63.	1.9	48
27	Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416. <i>Clinical Cancer Research</i> , 2005, 11, 7938-7944.	3.2	47
28	RET Mutation and Expression in Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1316-1323.	0.5	43
29	Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1459-1466.	1.3	42
30	Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival. <i>Clinical Cancer Research</i> , 2014, 20, 5124-5132.	3.2	39
31	The Association and Nuclear Translocation of the PIAS3-STAT3 Complex Is Ligand and Time Dependent. <i>Molecular Cancer Research</i> , 2009, 7, 1854-1860.	1.5	35
32	Protein inhibitor of activated STAT3 expression in lung cancer. <i>Molecular Oncology</i> , 2011, 5, 256-264.	2.1	35
33	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 1108-1115.	1.0	33
34	Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. <i>Lung Cancer</i> , 2007, 56, 377-381.	0.9	32
35	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1163-1164e.	1.9	32
36	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e489-e501.	1.1	32

#	ARTICLE	IF	CITATIONS
37	Phase I Clinical and Pharmacokinetic Study of Rebeccamycin Analog NSC 655649 Given Daily for Five Consecutive Days. <i>Journal of Clinical Oncology</i> , 2001, 19, 2309-2318.	0.8	31
38	Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 141-148.	1.1	28
39	LY3022855, an anti-IL-6 colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. <i>Investigational New Drugs</i> , 2021, 39, 1057-1071.	1.2	26
40	PIAS3 expression in squamous cell lung cancer is low and predicts overall survival. <i>Cancer Medicine</i> , 2015, 4, 325-332.	1.3	25
41	Multi-Institutional Phase I Trials of Anticancer Agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 1926-1931.	0.8	24
42	Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. <i>International Journal of Cancer</i> , 2009, 125, 1728-1734.	2.3	23
43	CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 740-746.	1.9	23
44	Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 732-742.	4.3	23
45	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 1298-1303.	1.9	19
46	Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 1405-1414.	1.1	19
47	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	2.9	19
48	A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 55-60.	1.3	18
49	SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. <i>Anti-Cancer Drugs</i> , 2008, 19, 9-16.	0.7	17
50	A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2011, 29, 126-130.	1.2	17
51	Clinical Trial Design in Small Cell Lung Cancer: Surrogate End Points and Statistical Evolution. <i>Clinical Lung Cancer</i> , 2014, 15, 207-212.	1.1	17
52	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. <i>Cancer Medicine</i> , 2021, 10, 3862-3872.	1.3	17
53	Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e106784.	1.1	16
54	Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 435-441.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 744724.	1.3	15
56	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. <i>Radiotherapy and Oncology</i> , 2016, 121, 335-341.	0.3	14
57	Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. <i>Molecular Oncology</i> , 2018, 12, 2124-2135.	2.1	14
58	Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 73-78.	1.1	13
59	A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 4574-4584.	3.2	13
60	PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. <i>International Journal of Cancer</i> , 2014, 134, 1045-1054.	2.3	12
61	Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age > 65 years) using national SEER-Medicare data. <i>Practical Radiation Oncology</i> , 2016, 6, e163-e169.	1.1	12
62	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 738-747.	1.2	12
63	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1522-1534.	0.5	12
64	Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 195-209.	2.1	12
65	Hunting and Trapping the Vascular Endothelial Growth Factor. <i>Journal of Clinical Oncology</i> , 2010, 28, 185-187.	0.8	11
66	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
67	Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?. <i>Translational Lung Cancer Research</i> , 2019, 8, 710-714.	1.3	11
68	Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 135-142.	0.9	11
69	Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors. <i>Cancer Biology and Therapy</i> , 2011, 12, 139-151.	1.5	10
70	Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 547-553.	1.1	10
71	Beyond Adenocarcinoma: Current Treatments and Future Directions for Squamous, Small Cell, and Rare Lung Cancer Histologies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 147-162.	1.8	10
72	Relationship between phase I study duration and symptom burden. <i>Supportive Care in Cancer</i> , 2018, 26, 731-737.	1.0	10

#	ARTICLE	IF	CITATIONS
73	A first-in-human phase I and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 391-398.	2.9	10
74	Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2005, 23, 563-567.	1.2	9
75	Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. <i>Clinical Lung Cancer</i> , 2021, 22, 16-22.e1.	1.1	9
76	A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase I clinical trials. <i>Cancer Medicine</i> , 2021, 10, 4312-4321.	1.3	9
77	Phase I clinical trials in patients ≥80. <i>Journal of Geriatric Oncology</i> , 2011, 2, 142-146.	0.5	8
78	Oral Combination Chemotherapy in the Management of AIDS-Related Lymphoproliferative Malignancies. <i>Drugs</i> , 1999, 58, 99-107.	4.9	7
79	Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides. <i>JAMA Dermatology</i> , 2017, 153, 413.	2.0	6
80	Role of immunotherapy in gastroenteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12943.	1.2	5
81	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 166-166.	0.8	5
82	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9080-TPS9080.	0.8	5
83	Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 142-151.	1.2	4
84	Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities. <i>Molecular Oncology</i> , 2021, 15, 3545-3558.	2.1	4
85	Defining Subgroups of Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 750-751.	0.5	3
86	Genomic alterations in small cell lung cancer and their clinical relevance. <i>Translational Lung Cancer Research</i> , 2016, 5, 450-451.	1.3	3
87	Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience. <i>Clinical Imaging</i> , 2020, 68, 210-217.	0.8	3
88	First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 3063-3063.	0.8	3
89	Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients. <i>Journal of Clinical Oncology</i> , 2020, 38, e21680-e21680.	0.8	3
90	Combination chemotherapy with topotecan for non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 41, S23-S26.	0.9	2

#	ARTICLE	IF	CITATIONS
91	Ongoing Trials with Bevacizumab and Other Antiangiogenic Agents in Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S71-S75.	1.1	2
92	Trends in imaging utilization for small cell lung cancer: a decision tree analysis of the NCCN guidelines. <i>Clinical Imaging</i> , 2021, 75, 83-89.	0.8	2
93	Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. <i>Future Oncology</i> , 2021, 17, 2713-2724.	1.1	2
94	Phase I Trial of the Base " Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies. <i>Blood</i> , 2014, 124, 4688-4688.	0.6	2
95	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 51-58.	0.4	2
96	Abstract 2047: Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer. , 2020, , .		2
97	Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. <i>Clinical and Translational Science</i> , 2021, 14, 664-670.	1.5	2
98	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e129-e133.	1.1	1
99	A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3241.	1.2	1
100	Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8572-8572.	0.8	1
101	RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9081-TPS9081.	0.8	1
102	Temporal evolution of patient characteristics enrolled on phase I trials. <i>Investigational New Drugs</i> , 2011, 29, 312-315.	1.2	0
103	Slicing and dicing small cell lung cancer to improve trial outcomes. <i>Cancer</i> , 2020, 126, 3919-3921.	2.0	0
104	Pursuing Immunotherapeutic Targets in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1056-1057.	0.5	0
105	Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18046-e18046.	0.8	0
106	Clinical trial design in small cell lung cancer: Surrogate endpoints and statistical evolution.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7087-7087.	0.8	0
107	Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13521-e13521.	0.8	0
108	Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns. <i>Journal of Radiosurgery and SBRT</i> , 2021, 7, 271-277.	0.2	0